Replies to post #481 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

Definitely looking forward to the update on the outcomes from the discussions with the FDA.

You could be right. My perspective: When I hear that enrollment is ahead of schedule, I take that as total enrollment - both control and combo arms. Doesn't make sense for them to say that enrollment is ahead of schedule but there are issues with the control arm.

The metrics for Avastin are well supported by thousands of patients. They are well documented. I'd be surprised if VB-111's control arm with Avastin only shows anything different than the past results.

Thanks for your perspective. The upcoming announcement will shed light on all of this.